Kestra Medical Technologies (NASDAQ:KMTS) Trading 9.7% Higher – What’s Next?

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS)’s share price was up 9.7% during trading on Thursday . The stock traded as high as $20.33 and last traded at $20.6460. Approximately 33,193 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 315,223 shares. The stock had previously closed at $18.82.

Analysts Set New Price Targets

Several analysts have recently commented on KMTS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Monday, March 23rd. The Goldman Sachs Group decreased their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Kestra Medical Technologies currently has a consensus rating of “Hold” and a consensus target price of $27.40.

Kestra Medical Technologies Trading Up 8.1%

The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32. The company has a fifty day moving average of $20.68 and a 200-day moving average of $23.36. The firm has a market capitalization of $1.19 billion, a PE ratio of -5.14 and a beta of 0.83.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.01). Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The firm had revenue of $24.55 million for the quarter. The firm’s revenue for the quarter was up 62.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.34 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction on Friday, May 15th. The stock was sold at an average price of $20.96, for a total transaction of $314,400.00. Following the completion of the sale, the insider directly owned 334,786 shares in the company, valued at approximately $7,017,114.56. This trade represents a 4.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 45,000 shares of company stock worth $919,050 in the last ninety days. 3.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kestra Medical Technologies

Hedge funds have recently bought and sold shares of the business. Farther Finance Advisors LLC bought a new position in shares of Kestra Medical Technologies in the fourth quarter worth about $31,000. Russell Investments Group Ltd. raised its holdings in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after acquiring an additional 474 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Kestra Medical Technologies in the 3rd quarter valued at approximately $48,000. BNP Paribas Financial Markets grew its stake in shares of Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after purchasing an additional 1,638 shares during the period. Finally, Daiwa Securities Group Inc. bought a new stake in shares of Kestra Medical Technologies in the 4th quarter valued at approximately $72,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.